Plain-English translation of NCT07932002 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a Phase 4 clinical trial testing , a medication that works by regulating the body's immune response. The study aims to see if this treatment can help reduce neurological symptoms—such as fatigue, brain fog, or nerve-related problems—that people may experience after having COVID-19. You would receive the medication as an intravenous infusion (through an IV) on a regular schedule over several months.
Some people develop persistent neurological symptoms after COVID-19 infection, and current treatments have not adequately addressed these problems. Researchers believe this medication may help by reducing inflammation and immune system overactivity linked to these lingering symptoms.
You likely qualify if…
You likely don't qualify if…
You would come to the study center once per week for 24 weeks (about 6 months) to receive an intravenous infusion of the medication. Each infusion takes place about one week apart. During these visits, your medical team will monitor how you respond to treatment and track any changes in your symptoms. The entire study period is approximately 30 weeks, including follow-up time after your final infusion.
AI-generated summary from trial data · Nov 13, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
IMMUNOe Research Centers
Enrollment target
~30 participants
Started
November 2025
Primary completion
July 2027
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in November 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.